English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
Prior clinical trials of TEPEZZA(TM) have enrolled patients with a new diagnosis of thyroid eye disease. This one is recruiting patients who have been diagnosed for at least three years – but less than eight – to assess the effectiveness on inactive/chronic TED.
https://clinicaltrials.gov/ct2/show/NCT04583735
myBinderRelated Content
-
Breakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...
-
Teprotumumab for Treatment of Thyroid Eye Disease Meets Endpoints in Phase 3 StudyResults from the phase 3 OPTIC study sho...
-
Early Experience With Teprotumumab for Chronic Thyroid Eye DiseasePurpose: To report the first case of a ...
-
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
-
TEPEZZA (teprotumumab-trbw)- Frequently Asked Questions1. What is TEPEZZA? TEPEZZA is the firs...
-
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 ResultsHorizon Therapeutics plc today announced...
-
TEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
